Fig 1.
CONSORT flow diagram of participants through the study.
Table 1.
Demographic characteristics, prior seasonal influenza vaccine, and study site, by study group.
Table 2.
Haemagglutination inhibition (HI) data by study group, intention-to-treat analysis.
Table 3.
Haemagglutination inhibition (HI) data by study group, per protocol analysis.
Fig 2.
HI antibody against H7N9 reverse cumulative distribution curve after 28(+7) days post 2nd dose administration, intention-to-treat.
Fig 3.
HI antibody against H7N9 reverse cumulative distribution curve after 28(+7) days post 2nd dose administration, per protocol analysis.
Fig 4.
Association of HI seroprotection rate after 28(+7) days post 2nd dose administration with prior receipt of seasonal influenza vaccine, intention-to-treat analysis.
Fig 5.
Association of HI seroprotection rate after 28(+7) days post 2nd dose administration with prior receipt of seasonal influenza vaccine, per protocol analysis.
Fig 6.
MNT antibody against H7N9 reverse cumulative distribution curve after 28(+7) days post 2nd dose administration, intention-to-treat.
Fig 7.
MNT antibody against H7N9 reverse cumulative distribution curve after 28(+7) days post 2nd dose administration, per protocol analysis.
Table 4.
Microneutralization (MN) data by study group, intention-to-treat analysis.
Table 5.
Microneutralization (MN) data by study group, per protocol analysis.
Table 6.
Demographic characteristics, prior seasonal influenza vaccine, and study site, by study group.